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Abstract 
The ability of human mesenchymal stromal/stem cells (hMSCs) to 
differentiate into various mesenchymal cell lineages makes them a promising cell 
source for the use in tissue repair strategies. Because the differentiation potential of 
hMSCs differs between donors, it is necessary to establish biomarkers for the 
identification of donors with high differentiation potential. Here, we show that 
microRNA (miRNA) expression levels are effective for distinguishing donors with 
high differentiation potential from low differentiation potential. Twenty human MSC 
donors were initially tested for marker expression and differentiation potential. In 
particular, chondrogenic differentiation potential was evaluated on the basis of 
histological matrix formation, mRNA expression levels of chondrogenic marker 
genes, and quantitative glycosaminoglycan deposition. Three donors out of twenty 
were identified as donors with high chondrogenic potential, whereas nine showed 
moderate and eight low chondrogenic potential. Expression profiles of miRNAs 
involved in chondrogenesis and cartilage homeostasis were used for the distinction 
between high-performance hMSCs and low-performance hMSCs. Global mRNA 
expression profiles of the donors before the onset of chondrogenic differentiation 
revealed minor differences in gene expression between low and high chondrogenic 
performers. However, analysis of miRNA expression during a seven-day 
differentiation period identified miR-210 and miR-630 as positive regulators of 
chondrogenesis. In contrast, miR-181 and miR-34a, which are negative regulators of 
chondrogenesis, were upregulated during differentiation in low performing donors. In 
conclusion, profiling of hMSC donors for a specific panel of miRNAs may have 
prognostic value for selecting donors with high differentiation potential to improve 
hMSC-based strategies for tissue regeneration. 
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Introduction 
Human mesenchymal stromal/stem cells (hMSCs) are a multipotent cell 
source that can be easily harvested from various locations of the body, including bone 
marrow, periosteum, synovium, synovial fluid, adipose tissue, bucal fat pad, 
infrapatellar fat pad and osteoarthritic cartilage [1-6]. The ability of hMSCs to 
differentiate into mesenchymal tissues such as bone and cartilage, and their potential 
as trophic mediators, renders them particularly suitable for tissue engineering [7]. 
Unfortunately, large inter-donor variation of differentiation potential is a general 
complication for the practical implementation of hMSC-based tissue engineering 
approaches [8,9]. Donor age, method or location of harvest, culture conditions as well 
as culture time are known to affect the differentiation potential of hMSCs [10-16]. 
Jansen and colleagues suggested that distinctions in mRNA gene expression profiles 
might be predictive for differentiation potential [17]. However, specific biomarkers 
indicative for differentiation potential of undifferentiated hMSCs remain to be 
defined.  
Studies on the genetic and epigenetic mechanisms that control the 
differentiation potential of hMSCs have focused on characterizing variation in both 
mRNA and miRNA expression levels [18-21]. MicroRNAs (miRNAs) control cell 
fate by negatively regulating protein accumulation through effects on the stability 
and/or translation of mRNAs for transcription factors and their phenotypic target 
genes. Hence, miRNAs are very relevant molecular candidates for mapping the 
proliferation and differentiation potential of hMSCs. 
In this study we tested a series of bone marrow derived hMSCs from a cohort 
of donors for their potential to undergo chondrogenesis. This cohort has previously 
been characterized in great detail with respect to osteogenic, adipogenic, endothelial 
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cell differentiation potential and CD marker expression [22,23] and meets the criteria 
proposed by the Mesenchymal and Tissue Stem Cell Committee of the International 
Society for Cellular Therapy [24]. Like for differentiation into other cell types, the 
chondrogenic potential varied significantly between donors. The biological properties 
of these hMSCs were correlated with global mRNA expression profiles using 
microarray assays and qPCR expression analysis of a select panel of miRNAs. To 
permit identification of miRNAs with predictive value for chondrogenic 
differentiation, we examined miRNA expression both before the onset of 
differentiation and after the induction of chondrogenic differentiation at day seven in 
pellet culture. We found that miRNA profiling of hMSC donors and patients may 
have prognostic value in regenerative medicine by permitting identification of hMSCs 
that are most effective in supporting differentiation.  
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Materials and Methods 
 
Cell expansion and differentiation 
The use of human bone marrow aspirates was approved by local Medical Ethics 
Committee with written informed consent by the donors [25]. Aspirates were 
retrieved during total hip replacement surgery from the acetabulum or iliac crest 
(average age: 52 years, 25% male, 75% female). Aspirates were resuspended using a 
20G needle and plated at a density of 0.5 million mononucleated cells/cm2. MSCs 
were selected by plastic adherence in proliferation media (α-MEM, 10% fetal bovine 
serum (Lonza, Verviers, Belgium), 0.2 mM ascorbic acid, 2 mM L-glutamine, 100 
U/mL penicillin, 100 mg/mL streptomycin, and 1 ng/mL of basic Fibroblast Growth 
Factor (Instruchemie, Delfzijl, The Netherlands). Human MSCs were expanded up to 
passage 2 and used in passage 3 to test their differentiation potential. The 
determination of cell surface marker expression (CD105, CD11b, CD19, CD45, 
HLA-DR, CD90, CD73, CD34), osteogenic potential, adipogenic potential and 
endothelial induction of the used hMSC donors is described elsewhere [22,23].  
 
 
Chondrogenic differentiation 
To induce chondrogenic differentiation, 250,000 hMSCs were seeded in round bottom 
96 well plates [26] at passage 2. Pellets were formed by centrifugation (500 rcf, 5 
min) and maintained in chondrogenic differentiation media. This medium consists of 
Dulbecco’s modified Eagle’s medium supplemented with 40 mg/mL of proline, 50 
mg/mL ITS-premix, 50 mg/mL of ascorbic acid, 100 mg/mL of sodium pyruvate, 
100U penicillin/mL, and 100 mg/mL streptomycin, 10 ng/mL of transforming growth 
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factor-β and 10-7 M of dexamethasone. Cells were cultured for four weeks for 
determination of GAG deposition (quantitative and qualitative) and qPCR of 
chondrogenic markers and one week for the qPCR analysis of chondrogenesis-related 
miRNAs as previously described [26]. Media was changed twice a week. 
 
Histology- Alcian Blue staining 
After four weeks of chondrogenic culture pellets were fixed with 10% buffered 
formalin for 15 min, dehydrated and embedded in paraffin using routine procedures. 
Sections of 5 µm were cut and stained for sulfated glycosaminoglycans (GAGs) with 
Alcian Blue (0,5 %, in H2O, pH=1 adjusted with HCl, 30 min) combined with 
counterstaining of Nuclear Fast Red (0.1% in 5% aluminum sulfate, 5 min). Scoring 
of histology was performed by three independent blinded observers according to the 
intensity of Alcian Blue staining and morphology of the formed pellets. 
 
mRNA isolation and quantitative polymerase chain reaction 
After four weeks of chondrogenic culture total RNA was isolated from pellet cultures 
with the Nucleospin RNA II kit (Bioke) and 1 μg RNA was reverse-transcribed into 
cDNA using the iScript cDNA Synthesis kit (Bio-Rad) according to the 
manufacturer’s protocols. The primers for quantitative polymerase chain reaction 
(qPCR) are listed in table 1. mRNA expression levels were normalized with GAPDH 
and B2M as housekeeping genes. 
All reagents were purchased from Invitrogen unless otherwise stated. Common 
chemicals were purchased from Sigma-Aldrich.  
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Microarray expression profiling  
Gene expression profiling of 20 hMSC donors was carried out using the Affymetrix 
microarray platform. RNA isolated at passage 2 before the initiation of the 
chondrogenic differentiation was hybridized to the Human Genome U133A 2.0 Array 
(Affymetrix) and scanned with a GeneChip G3000 scanner (Affymetrix). 
Measurements were normalized for technical effects related to efficiency of 
hybridization and amplification of nucleic acids, as well as the physical location on 
the array. Data processing and statistical testing were performed using R and 
Bioconductor statistical software (www.bioconductor.org). Analysis to determine 
differential gene expression was performed using a linear modelling approach with 
empirical Bayesian methods, as implemented in the Limma package [27] and 
described in more detail in [22]. Raw and normalized data have been deposited in the 
Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/, GSE39540). 
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) was used to 
investigate the predicted gene-gene interaction network [28,29]. Clusters were formed 
using Markov clustering algorithms. Changes in upstream regulators and bio-
functions were visualized using Ingenuity Pathway Analysis software (IPA
®
, 
Ingenuity Systems). 
The here described data set was previously used by Portalska et al. and 
Mentink et al. [22,23]. We reanalysed this dataset after the formation of two groups: 
good and low chondrogenic performing hMSC donors. To correlate donor variation 
with chondrogenic differentiation ability, we scored different donor-derived hMSCs 
based on their histological pellet culture appearance, glycosaminoglycan deposition 
and expression of mRNA markers of chondrogenesis after 28 days of differentiation. 
Subsequently, a list of genes ranked on fold change between the highest and lowest 
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chondrogenically-performing donors was generated using the approach described 
above. 
 
MicroRNA isolation and quantitative polymerase chain reaction 
Small RNAs were isolated from monolayer hMSC cultures at passage 2 and from 
pellet cultures at day seven after initiation of chondrogenic differentiation with the 
AllPrep DNA/RNA/Protein Mini Kit in combination with the RNeasy® MinElute® 
Cleanup Kit according to the manufacturers protocol (Qiagen). Nucleic acid 
concentrations were measured with the Nanodrop2000. The small RNA fraction 
cDNA was prepared using revertAid H minus first strand cDNA synthesis kit 
(Fermentas). SYBR (N’,N’-dimethyl-N-[4-[(E)-(3-methyl-1,3-benzothiazol-2-
ylidene)methyl]-1-phenylquinolin-1-ium-2-yl]-N-propylpropane-1,3-diamine) green 
mRNA Primer sequences are listed in Table 2. QuantimiR-RT kit (Systems 
Biosciences (SBI)) was used according to manufacturer’s instruction to convert small 
RNAs into cDNA. Expression levels were analyzed by qRT-PCR (SYBR Green 
supermix and iCycler IQ detection system; Bio-Rad) using conventional protocols 
[30]. The relative expressions were calculated by ΔCT method normalized to U6 
expression.  
The qRT-PCR data were analysed using an one-way ANOVA with Tukey as post-hoc 
test (different sized groups) in SPSS. Significance levels of p≤0.05 are indicated with 
an asterisk (*).  
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Results 
Limited chondrogenic potential of hMSCs donors  
hMSCs from a cohort of twenty donors were tested previously for their 
endothelial, adipogenic, osteogenic and chondrogenic differentiation potential. All 
donor-hMSCs expressed the anticipated CD marker profile of hMSCs [22,23]. We 
compared chondrogenic potential in depth based on histological appearance, 
glycosaminoglycans (GAG) deposition and chondrogenic mRNA expression. This 
analysis revealed that only three donors show substantial chondrogenesis after 28 
days of pellet culture. Another nine donors show moderate levels of chondrogenesis 
and eight donors have only a low potential to undergo chondrogenesis (Fig S1). 
Alcian Blue stain for GAG of two representative donors of each group revealed that 
intensity of staining is decreasing from donors with high chondrogenic potential to 
donors with low chondrogenic potential. Reduction in GAGs is parallelled by limited 
abundance of encapsulated chondrocyte units (i.e., reduced chondron formation), 
increased fibrous cartilage formation and a higher cell to matrix ratio (Fig 1A).  
Gene expression levels of the chondrogenic genes ACAN and COL2A1 were 
significantly upregulated in donors with high chondrogenic potential. The 
chondrogenic transcription factor SOX9 and FRZB, a recently identified marker for 
articular cartilage, were non-significantly higher expressed in good chondrogenic 
performers. COL10A1, a marker for cartilage hypertrophy was significantly higher 
expressed in high performing donors. COL1A1, a de-differentiation marker exhibits 
limited variation in expression between the different groups (Fig 1B). Donors with 
high chondrogenic potential show distinct quantitative GAG levels from moderate 
and low performers (Fig. 1C). Histologically assessed GAG levels did not distinguish 
moderate from low performing donors (Fig 1C). Thus, high-performing chondrogenic 
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hMSCs are distinct from biologically low-performing hMSCs by both histochemical 
and molecular criteria. 
 
 
Microarray-based mRNA expression profiling shows limited distinctions between 
hMSCs with different chondrogenic potential. 
Analysis of global gene expression levels between all 20 donors revealed 
minor mRNA expression differences between the high, moderate and low performing 
donors. To improve detection of molecular differences,  we compared mRNA levels 
upon biological stratification of the donors into two groups with either high or low 
chondrogenic potential (n=3 in each case) using the extremes at both ends of the 
spectrum of chondrogenic differentiation based on histology, quantitative GAG 
assessment and gene expression analysis.  Statistical evaluation of these highly 
distinct groups increased the number of significantly differentially expressed genes 
but differences in global gene expression levels were small (Table S1). STRING 
network analysis of genes with a minimal 1.6 fold (log ratio 0.5) upregulation in 
donors with high chondrogenic potential compared to low-performing donors 
demonstrated changes in regulatory networks associated with transcriptional control 
and signal transduction. One major network includes the basic helix loop-helix family 
member E40 (BHLHE40), which is a transcription factor modulating chondrogenesis 
[31]. Furthermore, several other gene regulatory factors were identified, such as 
nuclear receptor group 4A2 (NR4A2, also known as NURR1), as well as the basic 
leucine zipper (bZIP) proteins ATF3, MAFB, FOSB and FOS.  Each of these 
regulators have been linked to signal transduction, cell proliferation and 
differentiation [32] (Fig 2A). Network analysis of genes with a minimal 1.4 fold 
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downregulation in donors with low chondrogenic potential compared to donors with 
high chondrogenic potential revealed major networks associated with extracellular 
matrix proteins, such as ACAN, COL4A1, TIMP3 and EFEMP1, as well as a network 
of signalling proteins JAG1, dickkopf-related protein 1 (DKK1), and tumor-necrosis 
factor receptor superfamily member 11B (TNFRSF11B, also known as 
osteoprotegerin/OPG) (Fig 2B). Ingenuity pathway analysis revealed that the ten most 
differentially regulated cellular functions between the three high- and the three low 
performing donors were linked to development, as well as cell growth and survival 
(Fig 2C). TGFβ1 was identified as a major upstream contributor to the differences in 
gene expression between donors with high and low chondrogenic potential (Fig 2D).  
 
 
Differential expression of miRNAs between groups with distinct chondrogenic 
potential 
Since mRNA expression changes did not reveal clear markers of chondrogenic 
potential, we investigated the potential of miRNA expression as markers of 
chondrogenic potential in hMSCs. The expression of previously identified miRNAs 
known to be involved in chondrogenesis was evaluated before onset of chondrogenic 
differentiation and after seven days in a three dimensional cell mass under 
chondrogenic conditions (‘pellet culture’). MicroRNA levels of the same 3 donors 
with high chondrogenic potential (n=3) were compared with the same 3 donors with 
lowest chondrogenic potential (n=3). Two miRNAs, which are known to negatively 
influence osteoblast and chondrocyte differentiation (miR-30b and -221), display a 
higher expression in high-performing donors before the onset of chondrogenesis (fold 
upregulation high-performing donor/ low-performing donor: miR-30b: 1.63, miR-221: 
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1.83). Both miRNAs were strongly downregulated during chondrogenic 
differentiation (fold downregulation day 0 / day 7: miR-30b: 4.10, miR-221: 7.86). 
However, these same miRNAs were not or weakly downregulated in low-performing 
chondrogenic donors, marked by a lower fold-change between day 0 and day 7 after 
induction of chondrogenic differentiation. (fold downregulation day 0 /  day 7: miR-
30b: 0.94, miR-221: 2.72). 
 
One set of miRNAs (miR-34a, -23b, -26, -181) was more highly expressed in donors 
with high chondrogenic potential before the onset of chondrogenesis (fold difference 
between high- versus low-performing donors: miR-34a: 2.46-fold, miR-23b: 1.25-
fold, miR-26: 1.54-fold, miR-181: 1.15-fold). These miRNAs were all downregulated 
during differentiation (fold downregulation day 0 / day 7: miR-34a: 3.70-fold, miR-
23b: 1.67-fold, miR-26: 1.20-fold, miR-181: 1.10-fold). Remarkably, while their 
expression in poor performing donors was lower compared to good performing 
donors before the onset of chondrogenic differentiation, their expression was 
upregulated during differentiation (fold upregulation day 0 / day 7: miR-34a: 1.90-
fold, miR-23b: 1.30-fold, miR-26: 1.60-fold, miR-181: 1.39-fold). Notably, miR-34a 
and -23b are known to negatively influence cartilage homeostasis and/or 
chondrogenic differentiation. In contrast, expression of miR-630, a positive regulator 
of chondrogenesis, and miR-210, a marker of the hypoxic cell response is upregulated 
during chondrogenesis (fold upregulation day 0 / day 7: good donors miR-630: 1.99, 
miR-210: 14.14; low donors: miR-630: 3.52, miR-210: 21.93). Remarkably, their 
upregulation was even more pronounced in the poor performing donors, 
demonstrating discordance. Other regulators of chondrogenesis (miR-140, -145 and 
let-7e) display only minor differences between the different groups (Fig 3, Table 3). 
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Discussion 
By the comparison of the chondrogenic differentiation potential of previously well 
characterized hMSCs from a cohort of human donors (n=20), it was shown that only 15% of 
these donors provide hMSCs with the natural capability to undergo efficient chondrogenic 
differentiation ex vivo [22,23], while chondrogenic performance was moderate (45%) or even 
poor in the remaining donors (40%). Good chondrogenic differentiation potential was mainly 
marked by increased GAG deposition, better histological cartilage formation including 
increased formation of matrix encapsulated chondrocytes (i.e., chondron formation), limited 
fibrous cartilage formation, as well as the significantly higher mRNA expression of ACAN 
and COL2A1. The main focus of our study was therefore to define molecular differences that 
predict high differentiation hMSC donors at the start of the differentiation experiment. We 
would like to emphasize that this pool of MSCs was isolated from bone marrow biopsies by 
virtue of plastic adherence using protocols routinely applied for isolation and culture 
expansion of bone marrow MSCs for clinically practice [33]. Our MSCs were not clonally 
selected and they are likely to present a heterogenic cell population as previously noted 
[24].Previous studies have mainly focused on the osteogenic differentiation of hMSC donors. 
In these studies only differences in differentiation potential were noticed and no scoring was 
done. Differences in performances were shown to be independent of donor age, gender, and 
source of isolation [9,22,34]. As demonstrated by our co-workers [22] high osteogenic 
potential of a particular donor does not imply that this donor also exhibits high chondrogenic, 
adipogenic or endothelial differentiation potential. We therefore want to emphasize that 
prognostic markers have to be identified for each differentiation linage separately.  
In our study, we tested if donors with high chondrogenic potential could be identified 
in a pool of donors based on their global gene expression profile determined by Affymetrix 
microarray analysis before the onset of differentiation. Groups with high and low 
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chondrogenic differentiation potential separated with a maximum 1.6-log ratio in transcript 
expression levels (Table S1). Donors with low chondrogenic potential mainly exhibited 
higher expression of matrix associated proteins. Donors with high chondrogenic potential 
showed increased expression of mRNAs involved in transcriptional processes although 
overall differences were small. Two regulatory networks that differ between the donor groups 
with high and low chondrogenic potential are centered around the basic helix loop-helix 
family member E40 (BHLHE40) as a transcriptional factor modulating chondrogenesis [31] 
and the transcription factors FOS, FOSB and ATF3, which have general roles in signal 
transduction, cell proliferation and differentiation [35] (Fig 2A). FOS and ATF members are 
leucine zipper proteins that dimerize with the JUN family and thereby form a large number of 
AP-1 related transcription factor complexes. The activation of AP-1 is linked to terminal 
chondrocyte differentiation and cartilage homeostasis by modulating MMP13 expression 
[36]. Modulation of this transcription factor network may therefore have impact on 
chondrogenic performance of hMSCs. Hence, subtle differences in expression of transcription 
factors may contribute to distinctions in chondrogenic potential of hMSCs. 
Our studies suggested that genes that differ between donors with high or low 
chondrogenic potential are linked to TGFβ1 as a principal upstream regulator. TGFβ-
signalling supports embryonic development and cartilaginous matrix formation [37]. It is 
plausible that differences in TGFβ-responsiveness of hMSC donors might lead to distinct 
chondrogenic performance of hMSCs. Indeed, exogenous supplementation of TGFβ is a main 
driver of chondrogenic differentiation in hMSC pellet cultures [38]. Additionally, TGFβ is a 
key upstream regulator of AP-1 activity through its downstream effectors SMAD2 and 
SMAD3 [39]. Thus, differences in the TGFβ/SMAD/AP1 regulatory axis could account in 
part for differences in the chondrogenic ability of hMSCs from different donors.  
 Page 17 of 47 
St
em
 C
el
ls 
an
d 
D
ev
el
op
m
en
t
M
ic
ro
RN
A
 L
ev
el
s a
s P
ro
gn
os
tic
 M
ar
ke
rs
 fo
r t
he
 D
iff
er
en
tia
tio
n 
Po
te
nt
ia
l o
f H
um
an
 M
es
en
ch
ym
al
 S
tro
m
al
 C
el
l D
on
or
s (
do
i: 1
0.1
08
9/s
cd
.20
14
.05
34
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
18 
 
We next extended our analysis by analysis of a selected panel of miRNAs previously 
implemented in chondrogenic differentiation, including miR-210, miR-630 and miR-140 [40-
43]. We confirmed positive regulation of miR-210 and miR-630 within seven days after 
chondrogenic induction, with miR-630 being slightly higher expressed in good donors. 
Bakhshandeh and colleagues showed that miR-630 is part of a chondrogenic miRNA 
signature [43]. Among the pathways predicted to be targeted by miR-630 are erbB signalling, 
gap-junction communication, MAP-Kinase signaling and TGFβ signaling. Both MAP-
Kinase/Erk signaling and TGFβ-signaling are mediators of early stages of chondrogenic 
differentiation [44,45].  
We find that miR-181 and miR-34a, which are negative regulators of chondrogenesis, 
were upregulated during differentiation in low performing donors. Of these two, miR-34a 
perturbs cartilage homeostasis by inducing apoptosis, cell cycle arrest and senescence while 
targeting for E2F3, cyclin E2, CDK6 and others [46,47], but is otherwise unremarkable. 
However, similar to one of the predicted functions for miR-630, miR-181 acts as a negative 
regulator of the TGFβ pathway [43]. Thus, our current findings converge on a hypothetical 
molecular model in which miR-630 and miR-181, as well as the TGFβ/SMAD/AP-1 
regulatory axis, may form a tightly connected network that modulates and predicts the 
chondrogenic potential of hMSCs from different donors. 
In conclusion, our findings indicate that a panel of microRNAs encompassing miR-
210, miR-630, miR-181 and miR-34a can be informative for prognostically separating high-
performing hMSCs from low-performing hMSCs. Our data suggests that a short pre-clinical 
differentiation period of seven days suffices to provide insight into chondrogenic potential of 
different hMSCs based on miRNA expression profiling. Furthermore, modulation of TGFβ 
responsiveness appears to be a common mechanistic denominator in both the observed 
differences in mRNA expression profiles and the differences in miRNA expression between 
 Page 18 of 47
St
em
 C
el
ls 
an
d 
D
ev
el
op
m
en
t
M
ic
ro
RN
A
 L
ev
el
s a
s P
ro
gn
os
tic
 M
ar
ke
rs
 fo
r t
he
 D
iff
er
en
tia
tio
n 
Po
te
nt
ia
l o
f H
um
an
 M
es
en
ch
ym
al
 S
tro
m
al
 C
el
l D
on
or
s (
do
i: 1
0.1
08
9/s
cd
.20
14
.05
34
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
19 
 
biologically distinct hMSCs from different donors. We anticipate that experimental and 
therapeutic manipulation of TGFβ dependent miRNA/transcription factor networks may be 
useful for enhancing the chondrogenic potential of hMSCs and minimizing the biological 
differences among diverse patients that will undergo autologous tissue regeneration using 
hMSCs.  
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Figure Legends 
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Figure 1: 
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Comparison of twenty hMSC donors for their chondrogenic potential based on 
histological appearance, mRNA expression and glycosaminoglycans (GAG) 
deposition. 
(A) Alcian Blue stain for GAG of two representative donors of each group: high 
chondrogenic potential to donors with moderate and low chondrogenic potential (B) 
Gene expression levels of the chondrogenic genes ACAN, COL2A1 and COL10A1 
were assessed with qPCR analysis using mRNAs. Data represent the three donors in 
the high performing group, nine donors in the moderate group and eight donors in the 
low performing group +/- SD (* p≤0.05). (C) GAG levels as overview for all 20 
donors: donors with high chondrogenic potential demonstrate distinct quantitative 
GAG levels compared to moderate and low performers. The average measure of three 
different pellets per donor +/- SD is illustrated. 
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Figure 2: 
Microarray mRNA analysis as result of the comparison of three high performing 
chondrogenic versus low performing chondrogenic donors. 
(A) STRING network analysis of genes with a minimal 1.4 fold upregulation in 
donors with high chondrogenic potential compared to unefficient performing donors. 
(B) STRING network analysis of genes with a minimal 1.4 fold downregulation in 
donors with low chondrogenic potential compared to donors with high chondrogenic 
potential. The number of connecting lines indicates the reported evidence of 
connection between displayed proteins. (C) Ingenuity pathway analysis of the top ten 
differentially regulated cellular functions between the three high- and the three low-
performing donors. (D) TGFβ1 was identified as a major upstream contributor to the 
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differentially regulated genes between donors with high and low chondrogenic 
potential.  
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Figure 3: 
miRNA level regulation of high-performing vs low-performing donors 
Expression of miRNAs known to be involved in chondrogenesis was evaluated before 
chondrogenesis and at day seven of chondrogenic pellet culture. miRNA levels of 
donors with high chondrogenic potential (n=3) were compared with donors with low 
chondrogenic potential (n=3). miR-30 ,-221, 34a, -23b , -26, -181 display a higher 
expression in high-performing donors before the onset of chondrogenesis and were 
strongly downregulated during chondrogenic differentiation.  
miR-630 and miR-210 are upregulated during chondrogenesis. Negative regulators of 
chondrogenesis (miR-145 and let-7e) are slightly downregulated during the 
differentiation process in high- and low-performing donors. Data represents the mean 
of three independent hMSC donors. 
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Figure S1 
Scoring of twenty donors according to their chondrogenic potential 
(A) Scoring was done using mRNA expression levels of chondrogenic marker genes 
(positive judgement for high expression of ACAN, COL2A1, FRZB and SOX9; low 
expression of COL10A1, COL1A1); histological scoring was done by three 
independent individuals based on amount of positive Alcian Blue stain as well as 
histological appearance of the cartilage matrix; for GAG scoring donors were 
separated into high levels, moderate levels and no level of GAG expression (B) based 
on the overall score the percentage of donors in each group was plotted, data for (B) 
was based on table in (C). 
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Table 1: primers used for qPCR  
Gene Symbol Primer sequence Length of amplicon 
ACAN 5' AGGCAGCGTGATCCTTACC 3' 
5' GGCCTCTCCAGTCTCATTCTC 3' 
136 bp 
COL1A1 5' GTCACCCACCGACCAAGAAACC 3' 
5' AAGTCCAGGCTGTCCAGGGATG 3' 
121 bp 
COL2A1 5' CGTCCAGATGACCTTCCTACG 3' 
5' TGAGCAGGGCCTTCTTGAG 3' 
122 bp 
COL10A1 5' GCAACTAAGGGCCTCAATGG 3' 
5' CTCAGGCATGACTGCTTGAC 3' 
129 bp   
SOX9 5' TGGGCAAGCTCTGGAGACTTC 3' 
5' ATCCGGGTGGTCCTTCTTGTG 3' 
98 bp 
FRZB 5' ACGGGACACTGTCAACCTCT 3' 
5' CGAGTCGATCCTTCCACTTC 3' 
155 bp 
GAPDH 5' CGCTCTCTGCTCCTCCTGTT 3' 
5' CCATGGTGTCTGAGCGATGT 3' 
 101 bp 
B2M 5' GACTTGTCTTTCAGCAAGGA 3' 
5' ACAAAGTCACATGGTTCACA 3' 
106 bp 
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Table 2: primers used for the qPCR of miRNA 
 
Micro-RNA Primer sequence 
Universal reverse primer 5’-GACGAGGACTCGAGCTCAAGCT-3’ 
Oligodt-adaptor 5’-GACGAGGACTCGAGCTCAAGCTTTTTTTTTTTTTTTTT-3’ 
U6 5’CGCAAGGATGACACGCAAATTC-3’ 
Mir-30b 5’- TGTAAACATCCTACACTCAGCT -3’ 
Mir-221 5’- AGCTACATTGTCTGCTGGGTTTC -3’ 
Mir-34a 5’- TGGCAGTGTCTTAGCTGGTTGT -3’ 
Mir-23b 5’- TGGGTTCCTGGCATGCTGATTT -3’ 
Mir-26 5’- TTCAAGTAATCCAGGATAGGCT -3’ 
Mir-181 5’- AACATTCAACGCTGTCGGTGAG -3’ 
Mir-210 5’- CTGTGCGTGTGACAGCGGCTGA -3’ 
Mir-630 5’- AGTATTCTGTACCAGGGAAGGT -3’ 
Mir-140 5’- TACCACAGGGTAGAACCACGG -3’ 
Mir-145 5’- GTCCAGTTTTCCCAGGAATCCCT -3’ 
Let-7e 5’- TGAGGTAGGAGGTGTATAGTT -3’ 
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Table 3: investigated miRNAs and their reported function 
miRNA  reported function References observed regulation 
miR-30b negative regulation of osteoblast differentiation [32] higher expressed in high performers at day 0 
miR-221 negative regulation of chondrocyte differentiation [33, 34] higher expressed in high performers at day 0,                                 
downregulated during differentiation in high performers;             
no regulation in low performers 
miR-34a regulates osteoarthritis pathogenesis [35] higher expressed in high performers at day 0,                  
upregulation in low performers during chondrogenesis 
miR-23b potentially  upregulated in OA;  
negative regulation of TGFβ and BMP signalling 
[36, 37] higher in high performers at day 0, 
upregulation in low performers during chondrogenesis 
miR-26 mediates cholesterol metabolism; 
hypoxic upregulation 
[38, 39] higher expressed in high performers at day 0, 
upregulation in low performers during chondrogenesis 
miR-181 regulation of TGFβ signaling in chondrocytes; 
downregulation during chondrogenesis; 
hypoxic upregulation 
[39-41] higher expressed in high performers at day 0, 
upregulation in low performers during chondrogenesis 
miR-210 upregulation during chondrogenesis 
cell survival of MSCs 
hypoxic upregulation 
[20, 34, 39] upregulation in both donor groups during chondrogenesis 
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miR-630 activation of TGFβ signaling in chondrocytes [40] upregulation during differentiation, higher upregulation in 
good responders 
miR -140 positive regulation of chondrogenesis; negative regulation of histone 
deacetylase 4 (HDAC4);  
regulation of OA pathogenesis and endochondral bone formation 
[42-44] higher expressed in high performers; decreased during 
chondrogenesis 
miR-145 negatively regulates chondrogenesis by targeting SOX9;  
downregulation during chondrogenesis 
[34, 41, 45] higher expressed in high performers; decreased during 
chondrogenesis 
Let-7e downregulation during chondrogenesis 
self renewal of stem cells 
[34, 46] higher expressed in low performers, downregulation 
during chondrogenesis 
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Table S1: mRNA microarray results: Regulated genes with log-ratio of difference 
between good and low performing donors of at least 0.5. According  significance 
levels for each gene are displayed, but genes were not selected on significance. 
Symbol 
Entrez Gene Name 
Log 
Ratio p-value 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 1.654 4.81E-02 
RPS4Y1 ribosomal protein S4, Y-linked 1 1.390 2.16E-01 
TRIB1 tribbles homolog 1 (Drosophila) 1.024 4.31E-02 
GAS1  growth arrest-specific 1 0.941 2.21E-02 
SRSF6 serine/arginine-rich splicing factor 6 0.935 3.54E-03 
COLEC12 collectin sub-family member 12 0.925 1.35E-01 
HES1  hairy and enhancer of split 1, (Drosophila) 0.915 3.55E-02 
PTGS2 prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase) 0.879 7.52E-02 
LRRC15 leucine rich repeat containing 15 0.850 1.58E-01 
CTSK cathepsin K 0.835 5.46E-02 
NR4A2 nuclear receptor subfamily 4, group A, member 2 0.834 1.16E-01 
ENPP1 ectonucleotide 
pyrophosphatase/phosphodiesterase 1 0.793 4.88E-02 
CH25H cholesterol 25-hydroxylase 0.785 8.53E-02 
BAALC brain and acute leukemia, cytoplasmic 0.782 3.07E-02 
FOS FBJ murine osteosarcoma viral oncogene 
homolog 0.763 2.17E-01 
IGFBP5 insulin-like growth factor binding protein 5 0.705 3.56E-03 
HAS1 hyaluronan synthase 1 0.703 1.01E-01 
TNC  tenascin C 0.696 3.37E-02 
SRPX sushi-repeat containing protein, X-linked 0.660 8.02E-03 
CTBP1 C-terminal binding protein 1 0.649 1.07E-01 
EIF1AY eukaryotic translation initiation factor 1A, Y-
linked 
0.647 2.06E-01 
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BHLHE40 basic helix-loop-helix family, member e40 0.637 8.87E-02 
RAB3B RAB3B, member RAS oncogene family 0.612 2.46E-02 
GSTT2/GSTT2B glutathione S-transferase theta 2 0.607 1.52E-03 
ETV1 ets variant 1 0.584 2.30E-02 
FBN2 fibrillin 2 0.583 2.25E-01 
MATN2 matrilin 2 0.580 7.64E-03 
MAFB v-maf musculoaponeurotic fibrosarcoma 
oncogene homolog B (avian) 0.566 5.12E-02 
DDX3Y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-
linked 0.558 2.96E-01 
FOSB FBJ murine osteosarcoma viral oncogene 
homolog B 0.550 2.10E-01 
OLFML3 olfactomedin-like 3 0.548 9.79E-02 
ATF3 activating transcription factor 3 0.544 1.43E-01 
INSIG1 insulin induced gene 1 0.536 1.82E-01 
PTN pleiotrophin 0.532 5.33E-03 
NUCKS1 nuclear casein kinase and cyclin-dependent kinase 
substrate 1 0.527 2.96E-02 
APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3B 0.524 3.67E-03 
ACAT2 acetyl-CoA acetyltransferase 2 0.524 3.96E-02 
EIF2S3 eukaryotic translation initiation factor 2, subunit 3 
gamma, 52kDa 0.513 8.23E-02 
PTX3 pentraxin 3, long -0.500 4.03E-01 
CNN1  calponin 1, basic, smooth muscle -0.504 1.78E-02 
ITGBL1 integrin, beta-like 1 (with EGF-like repeat 
domains) -0.516 7.01E-02 
TXNIP thioredoxin interacting protein -0.517 8.55E-02 
CYTL1 cytokine-like 1 -0.517 4.11E-01 
MCAM melanoma cell adhesion molecule -0.519 9.54E-02 
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TIMP3 TIMP metallopeptidase inhibitor 3 -0.520 4.11E-02 
IFI27 interferon, alpha-inducible protein 27 -0.521 1.71E-01 
FST follistatin -0.530 2.23E-01 
MFAP5 microfibrillar associated protein 5 -0.532 1.21E-01 
FHL1  four and a half LIM domains 1 -0.535 6.07E-02 
JAG1 jagged 1 -0.549 2.32E-01 
ACAN aggrecan -0.565 8.00E-02 
KRT18 keratin 18 -0.565 4.25E-01 
LTBP1 latent transforming growth factor beta binding 
protein 1 -0.567 1.19E-02 
EPAS1 endothelial PAS domain protein 1 -0.571 4.00E-02 
SLC7A11 solute carrier family 7 (anionic amino acid 
transporter light chain, xc- system), member 11 -0.573 6.99E-02 
DDIT4 DNA-damage-inducible transcript 4 -0.592 1.80E-01 
ASNS asparagine synthetase (glutamine-hydrolyzing) -0.600 1.83E-01 
LIMCH1 LIM and calponin homology domains 1 -0.600 1.12E-01 
EFEMP1 EGF containing fibulin-like extracellular matrix 
protein 1 -0.602 3.69E-02 
MTHFD2 methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 2, methenyltetrahydrofolate 
cyclohydrolase -0.607 4.80E-02 
C10orf116 chromosome 10 open reading frame 116 -0.617 3.85E-02 
CLIC3 chloride intracellular channel 3 -0.636 5.97E-03 
PSAT1 phosphoserine aminotransferase 1 -0.640 8.73E-02 
COL4A2 collagen, type IV, alpha 2 -0.655 2.86E-03 
DEPTOR DEP domain containing MTOR-interacting 
protein -0.670 1.54E-01 
SLC7A5 solute carrier family 7 (amino acid transporter 
light chain, L system), member 5 -0.686 4.01E-02 
COL1A1 collagen, type I, alpha 1 -0.700 9.37E-02 
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ALDH1A3 aldehyde dehydrogenase 1 family, member A3 -0.748 9.99E-02 
COL4A1 collagen, type IV, alpha 1 -0.749 2.43E-03 
KRT14 keratin 14 -0.776 6.33E-03 
PPP1R3C protein phosphatase 1, regulatory subunit 3C -0.783 7.34E-03 
DKK1 dickkopf 1 homolog (Xenopus laevis) -0.790 1.10E-01 
TNFRSF11B tumor necrosis factor receptor superfamily, 
member 11b -0.817 2.11E-02 
XIST X (inactive)-specific transcript (non-protein 
coding) -0.892 2.03E-01 
PTGIS prostaglandin I2 (prostacyclin) synthase -0.900 2.41E-02 
ELN elastin -0.923 3.67E-02 
RGS4 regulator of G-protein signaling 4 -0.949 2.08E-01 
SULF1 sulfatase 1 -0.994 7.93E-03 
STC2 stanniocalcin 2 -0.999 2.03E-02 
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